Your browser doesn't support javascript.
loading
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca, Vincenza; Wetterskog, Daniel; Castro, Elena; Scarpi, Emanuela; Romero-Laorden, Nuria; Gurioli, Giorgia; Jayaram, Anuradha; Lolli, Cristian; Schepisi, Giuseppe; Wingate, Anna; Casadei, Chiara; Lozano, Rebeca; Brighi, Nicole; Aragón, Isabel M; Marin-Aguilera, Mercedes; Gonzalez-Billalabeitia, Enrique; Mellado, Begoña; Olmos, David; Attard, Gerhardt; De Giorgi, Ugo.
Afiliação
  • Conteduca V; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy. Electronic address: vincenza.conteduca@irst.emr.it.
  • Wetterskog D; University College London Cancer Institute, London, UK.
  • Castro E; Prostate Cancer Research Unit, Spanish National Cancer Research Centre.
  • Scarpi E; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Romero-Laorden N; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Gurioli G; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Jayaram A; University College London Cancer Institute, London, UK.
  • Lolli C; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Schepisi G; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Wingate A; University College London Cancer Institute, London, UK.
  • Casadei C; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Lozano R; Centro Nacional Investigaciones Oncologica, Madrid, Spain.
  • Brighi N; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Aragón IM; Genitourinary Translational Research Unit, Institute of Biomedical Research, Malaga, Spain.
  • Marin-Aguilera M; Medical Oncology Department, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain.
  • Gonzalez-Billalabeitia E; Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia, Spain.
  • Mellado B; Medical Oncology Department, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain.
  • Olmos D; Prostate Cancer Research Unit, Spanish National Cancer Research Centre.
  • Attard G; University College London Cancer Institute, London, UK. Electronic address: g.attard@ucl.ac.uk.
  • De Giorgi U; IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Eur J Cancer ; 152: 49-59, 2021 07.
Article em En | MEDLINE | ID: mdl-34077818

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptores Androgênicos / Biomarcadores Tumorais / Neoplasias de Próstata Resistentes à Castração / Docetaxel Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptores Androgênicos / Biomarcadores Tumorais / Neoplasias de Próstata Resistentes à Castração / Docetaxel Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido